Iloperidone: A clinical overview

Journal of Clinical Psychiatry

Volumn 72, Issue SUPPL. 1, 2011, Pages 19-23

  Citrome, Leslie ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; CLARITHROMYCIN; CYTOCHROME P450 2D6; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; FLUOXETINE; HALOPERIDOL; ILOPERIDONE; KETOCONAZOLE; MUSCARINIC RECEPTOR; PAROXETINE; PLACEBO; RISPERIDONE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 6 RECEPTOR; SEROTONIN 7 RECEPTOR; ZIPRASIDONE;

AKATHISIA; BINDING AFFINITY; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG LABELING; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GLUCOSE BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; MAINTENANCE DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; TACHYCARDIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT GAIN; XEROSTOMIA;

EID: 84555218388     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.10075su1.04     Document Type: Review

References (17)

1. Corbett R, Hartman H, Kerman LL, et al. Effects of atypical antipsychotic agents on social behavior in rodents. Pharmacol Biochem Behav. 1993; 45(1):9-17. doi:10.1016/091-3057(93)9079-9 PubMed
2. Citrome L. Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion. Expert Opin Drug Metab Toxicol. 2010;6(12):1551-1564. doi:10.1517/1742525.2010.531259 PubMed
3. Citrome L. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic. Int J Clin Pract. 2009;63(8):1237-1248. doi:10.1/j.1742-1241.209.02142.x PubMed
4. Citrome L. Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic. Int J Clin Pract. 2010;64(6):707-718. doi:10.1/j.1742-1241.2010.0234.x PubMed
5. Novartis enters into agreement for exclusive US and Canadian rights to Fanapt(TM), an FDA-approved oral therapy for schizophrenia [media release, October 12, 2009]. Basel, Switzerland: Novartis Pharmaceuticals Corporation;. http://www.novartis.com/newsroom/media-releases/en/2009/1346595.shtml. Accessed December 20, 2010.
6. Fanapt [prescribing information]. Basel, Switzerland: Novartis Pharmaceuticals Corporation. http://www.pharma.us.novartis.com/product/pi/pdf/ fanapt.pdf. Revised April 2011. Accessed June 5, 2011.
7. Stahl SM. Stahl's Essential Psychopharmacology. 3rd ed. Cambridge, England: Cambridge University Press; 2008.
8. US Food and Drug Administration. Drug approval package Fanapt (iloperidone) tablets. June 12, 2009 http://www.accessdata.fda.gov/drugsatfda- docs/nda/2009/022192s000TOC.cfm. Accessed December 20, 2010.
9. Thompson A, Lavedan C, Volpi S. Absence of weight gain association with the HTR2C -759C/T polymorphism in patients with schizophrenia treated with iloperidone. Psychiatry Res. 2010;175(3):271-273. doi:10.1016/j.psychres.209.03. 020 PubMed
10. Potkin SG, Litman RE, Torres R, et al. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. J Clin Psychopharmacol. 2008;28(suppl 1):S4-S11. doi:10.1097/JCP.0b013e3181692787 PubMed (Pubitemid 351397671)
11. Cutler AJ, Kalali AH, Weiden PJ, et al. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol. 2008;28(suppl 1):S20-S28. doi:10.1097/JCP.0b013e318169d4ce PubMed (Pubitemid 351397673)
12. Citrome L, Meng X, Hochfeld M. Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis. Schizophr Res. 2011;131(1-3):75-81. doi:10.1016/j.schres.201.05.018 PubMed
13. Kane JM, Lauriello J, Laska E, et al. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. J Clin Psychopharmacol. 2008;28(suppl 1):S29-S35. doi:10.1097/JCP. 0b013e318169ca7 PubMed (Pubitemid 351397674)
14. Geodon [prescribing information]. New York, NY: Pfizer Inc. http://www.pfizer.com/files/products/uspi-geodon.pdf. Revised December 2010. Accessed June 4, 2011.
15. Citrome L. Drug safety evaluation of ziprasidone. Expert Opin Drug Saf. 2011;10(3):437-448. doi:10.1517/1474038.201.56014 PubMed
16. Weiden PJ, Cutler AJ, Polymeropoulos MH, et al. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials. J Clin Psychopharmacol. 2008;28(suppl 1):S12-S19. doi:10.1097/JCP.0b013e3181694f5a PubMed (Pubitemid 351397672)
17. Citrome L. Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications. Curr Drug Saf. 2009;4(3):229-237. doi:10.2174/1574860978906985 PubMed